n°173 | May 2023
In this issue:

Kyriakides: you have helped lift the shroud of silence about prostate cancer

European Health Commissioner addresses delegates at Europa Uomo General Assembly
31 May 2023

Prostate cancer early detection: 'Policy needs actions'

European Cancer Organisation President provides Cancer Plan update at Europa Uomo General Assembly
27 May 2023

New trial investigates effect of pausing ADT plus

Europa Uomo provides patient perspective in research
4 May 2023

Screening: 'Doing nothing is not an option'

Europa Uomo’s André Deschamps says building awareness is a priority
27 Apr 2023
Prostate Research and Treatments

A new primary test for early detection of prostate cancer in the USA

In the revised 2023 American Urological Association (AUA) guidelines for early detection of prostate cancer, Stockholm3 has been included as a primary test. The AUA stated that the PSA blood test remains the first-line screening test of choice and, at the same time, that Stockholm3 has a higher predictive accuracy compared to PSA alone, with the advantage of reducing unnecessary biopsies.

Read the press release here.

EAU Patient Day 2023

Patient Day sessions at EAU23 were the best attended on record. The EAU Patient Office participated in multiple sessions throughout the congress, hosted a Clinical Leadership Development Workshop and received further representation across a plenary and two thematic sessions. Dr. Rachel Giles, Chair International Kidney Coalition, received the very first EAU Patient Advocacy Medal of Excellence for her contributions to urological patient advocacy.EAU Patient Office Chair Eamonn Rogers wrote an article for Men’s Health about some of his takeaways. He wrote: ‘Effective communication between urologists and their patients is vital to improving treatment outcomes and long-term patient quality of life.’

New Prostatepedia on imaging

NASPCC, the National Alliance of State Prostate Cancer Coalitions, has published a new Prostatepedia which focuses on imaging. The issue focuses on two major advances that should both have major impacts on the care that men with prostate cancer receive.

EAU podcast on the 2023 EAU Guidelines for prostate cancer

In this podcast, Prof. Dr. Nicolas Mottet (FR) and Prof. Phil Cornford (GB) talk about active surveillance for low-risk prostate cancer patients to avoid over-treatment, as well as the PSMA staging process for high-risk disease. They caution on altering treatment without sufficient evidence. The importance of standardised MRI procedures and the need for quality control to avoid unnecessary biopsies is also discussed.

Europa Uomo News

New journal article about EUPROMS 2.0 findings

Europa Uomo initiated the Europa Uomo Patient Reported Outcome Study 2.0 (EUPROMS 2.0) in October 2021, collecting the self-reported perspective of prostate cancer (PCa) patients on physical and mental well-being after treatment outside a clinical trial setting, to inform future fellow patients about the impact of PCa treatment.

The EUPROMS 2.0 study confirmed that treatment for PCa mainly affects urinary incontinence, sexual function, fatigue, and insomnia. Such information can be used to direct toward a better patient-doctor relationship, to offer patients ready access to responsible information and a better understanding of their disease and treatment.
Read the article here.

New Europa Uomo Board

After the annual General Assembly in Larnaca, last May 25-28, 2023, the following persons form the board of Europa Uomo:

Chairman: Günther Carl (Germany)
Vice-Chairman 1: Erik Briers (Belgium)
Vice-Chairman 2: Nils Petter Sjoholt (Norway)
Secretary: Steven Lerys (France)
Treasurer: Ioannis Vanezos (Cyprus)
Board member: Tania Estapé (Spain)
Board member: Marko Koivuneva (Finland)
Board member: Cosimo Pieri (Italy)
Board member: Paulius Rakstys (Lithuania)

Advisor to the Board: André Deschamps

Ex-Officio members: Dr. Alberto Costa (ESO) & Prof. Van Poppel (EAU)

Items of Interest

Canadian survey about living with mCRPC

The survey is for patients who have experienced metastatic castration-resistant prostate cancer, and their caregivers.

The purpose is to provide the Canadian Cancer Survivor Network with insights and perspectives about living with and managing advanced metastatic castration-resistant prostate cancer (mCRPC) from patients and caregivers in order to complete a patient evidence submission for LYNPARZA (olaparib).

This survey should take approximately 10 minutes to complete and will remain open until May 31, 2023.

G7 Cancer launched

At the initiative of the French National Cancer Institute, as part of the ten-year cancer control strategy, G7 Cancer officially launched on 9th May. Bringing together organisations at the forefront of the fight against cancer, this group aims to strengthen cooperation between partners to accelerate the fight against the disease, and in particular to address the most complex challenges.

ASPI webinar on second opinions

In this ASPI webinar, “Second Opinions and Biopsies” held on 29th April, prostate cancer patient Larry White and his wife Nancy discuss a second opinion on a biopsy with Dr. Epstein.


All previous issues are available on website: www.europa-uomo.org/newsletters/